



**PEER-REVIEW REPORT**

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 77413

**Title:** Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 04611317

**Position:** Peer Reviewer

**Academic degree:** MD, MSc, PhD

**Professional title:** Associate Professor, Chief Physician

**Reviewer’s Country/Territory:** Thailand

**Author’s Country/Territory:** China

**Manuscript submission date:** 2022-05-03

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-06-07 03:19

**Reviewer performed review:** 2022-06-10 07:25

**Review time:** 3 Days and 4 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

### **SPECIFIC COMMENTS TO AUTHORS**

This case was interesting and very rare malignancy. The author did not mention regarding IRB issue. The overall detail of case was acceptable, however, the English language needed to be polished. For example, "Metzgeroth et al. summarized the data from 261 hepatoid adenocarcinoma cases in 2010[8]. The stomach (63%), ovary (10%), lung (5%), gallbladder (4%), pancreas (4%), and uterus are the most common sites (4%)" this sentence show that uterus is the most common site!!!! More example, "HAL is a rare primary adenocarcinoma of the lung that contains hepatocytes and can be associated with or without elevated AFP", it is mean that in the lung has hepatocytes inside. Another example, "Haninger et al. modified the diagnostic criteria for HAL in 2014, and they are now as follows: HAL can be simple HAC, but it can also be typical acinar or papillary adenocarcinoma, signet ring cell carcinoma, or neuroendocrine carcinoma; positive expression of liver differentiation markers and AFP is not required for diagnosis; it has the morphological characteristics of hepatocytes[9]", it is difficult to understand.



**PEER-REVIEW REPORT**

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 77413

**Title:** Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 00722239

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor

**Reviewer’s Country/Territory:** Japan

**Author’s Country/Territory:** China

**Manuscript submission date:** 2022-05-03

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-06-08 08:17

**Reviewer performed review:** 2022-06-12 14:19

**Review time:** 4 Days and 6 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
-------------------------------------	---

### **SPECIFIC COMMENTS TO AUTHORS**

The authors have reported a case of hepatoid adenocarcinoma of the lung (HAL) which is responsive to sorafenib. The case is very rare, interesting, and includes important clinical implications. I consider this manuscript has potential of publication. The figures of immunostaining which suggests HAL (especially, CK18, AFP, and GPC-3) should be presented. Overall English usage needs polishing.